ALXN - Alexion Pharmaceuticals, Inc.
103.21 0.00 (0.00%)
After hours: 4:49PM EST
| Previous Close | 102.16 |
| Open | 102.38 |
| Bid | 103.51 x 900 |
| Ask | 103.44 x 800 |
| Day's Range | 101.95 - 103.61 |
| 52 Week Range | 94.59 - 141.86 |
| Volume | 3,179,555 |
| Avg. Volume | 1,900,032 |
| Market Cap | 22.851B |
| Beta (5Y Monthly) | 1.75 |
| PE Ratio (TTM) | 9.65 |
| EPS (TTM) | 10.70 |
| Earnings Date | Apr 22, 2020 - Apr 26, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 142.63 |
- Zacks
Can Biotech ETFs Gain on Mixed Q4 Earnings Results?
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.
- Thomson Reuters StreetEvents
Edited Transcript of ALXN earnings conference call or presentation 30-Jan-20 12:30pm GMT
Q4 2019 Alexion Pharmaceuticals Inc Earnings Call
- American City Business Journals
In the highest ranks of Mass. corporate leadership, women still scarce
While women make up one-quarter of leadership teams among the 25 largest publicly traded companies in Massachusetts, they represent just 4 percent of CEOs, according to a new report.
- Zacks
Top Ranked Growth Stocks to Buy for February 4th
Top Ranked Growth Stocks to Buy for February 4th
- MoneyShow
Alexion- Short Term Disappointment but Long Term Opportunity
Alexion Pharmaceuticals (ALXN) is a biopharmaceutical company that researches and manufactures treatments of severe and rare health disorders; I consider this an undervalued growth stock, notes Crista Huff, editor of Cabot Undervalued Stocks Advisor.
- Simply Wall St.
Is Alexion Pharmaceuticals (NASDAQ:ALXN) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
- Simply Wall St.
Results: Alexion Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Last week, you might have seen that Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released its full-year result to the...
- Zacks
Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales
Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
- Zacks
Top Ranked Growth Stocks to Buy for January 31st
Top Ranked Growth Stocks to Buy for January 31st
- American City Business Journals
Families of rare-disease patients take on drug development, but face uphill battle
Frustrated with the slow pace of drug discovery and desperate to help their loved ones, untrained family members take the work into their own hands by starting biopharma companies. But few such companies have been successful.
- Investor's Business Daily
Alexion Stumbles On Mixed Outlook Despite Strong Fourth-Quarter Earnings
Alexion Pharmaceuticals topped Wall Street's fourth-quarter revenue and adjusted earnings expectations early Thursday, but Alexion Pharma stock slipped on mixed guidance for 2020.
- Zacks
Alexion (ALXN) Q4 Earnings Beat Estimates, Revenues Up Y/Y
Alexion (ALXN) beats on earnings and revenues in the fourth quarter of 2019.
- Benzinga
Recap: Alexion Pharmaceuticals Q4 Earnings
View more earnings on ALXN See more from Benzinga Recap: Alliance Data Systems Q4 Earnings AmerisourceBergen: Q1 Earnings Insights 17 Healthcare Stocks Moving In Thursday's Pre-Market Session © 2020 Benzinga.com. ...
- Zacks
Alexion Pharmaceuticals (ALXN) Q4 Earnings and Revenues Top Estimates
Alexion (ALXN) delivered earnings and revenue surprises of 3.44% and 1.72%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Alexion Reports Fourth Quarter and Full Year 2019 Results
Alexion Reports Fourth Quarter and Full Year 2019 Results
- Investing.com
Alexion Earnings, Revenue Beat in Q4
Investing.com - Alexion reported on Thursday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.
- American City Business Journals
$930 million sale of Blue Bell biopharma firm finalized
The purchase price could grow if the Food and Drug Administration approves an experimental therapy that combines a product from each company.
- Zacks
Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More
Let us take a look at five big drug/biotech companies due to release their quarterly results on Jan 30.
- Zacks
Why Earnings Season Could Be Great for Alexion (ALXN)
Alexion (ALXN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- Zacks
Top Ranked Growth Stocks to Buy for January 29th
Top Ranked Growth Stocks to Buy for January 29th
- Zacks
Acceleron (XLRN) Up on Success of PAH Drug in Phase II Study
Acceleron (XLRN) stock surges as sotatercept meets primary and secondary endpoints in a phase II study in patients with pulmonary arterial hypertension.
- Kiplinger
5 'Strong Buy' Biotech Stocks to Buy for 2020
Investors seeking out high growth for their portfolios will often turn to biotech stocks. The biotechnology industry, which has become densely populated as our understanding of living systems and organisms continues to expand, has earned a reputation on Wall Street for its explosive potential ... and high volatility.In contrast to companies in other sectors, the gains and losses in even the best biotech stocks hinge less on earnings results, and more on a few key indicators such as trial-data readouts or verdicts from regulatory agencies. Product approvals unlock vital revenues, so a single positive update can function as a catalyst that propels shares to new highs.Of course, there's a reason risk-averse investors shy away from these stocks: The opposite also holds true.Wall Street pros rightly advise a cautious approach when evaluating the biotechnology industries. We find that monitoring the analyst community can be helpful on a couple fronts: For one, we can see where the pros are putting their faith. Also, analysts can provide much-needed insight into many stocks that get little media coverage, and whose progress can be difficult to gauge unless you're a medical expert.We used TipRanks' Stock Screener tool to comb through hundreds of biotechnology stocks to identify promising picks - ones that have received enough lopsided support from analysts that they earn TipRanks' top Strong Buy consensus rating. Here, we have found five top biotech stocks with overwhelmingly bullish sentiment from the analyst community, and price-growth projections of between 28% and 82%. SEE ALSO: 8 Stock Picks Getting Hit by Coronavirus Fears
- Zacks
Can CF Drugs Drive Growth for Vertex (VRTX) in Q4 Earnings?
On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales uptake of its CF drugs and the unveiling plans for the newly-approved Trikafta triple combination regimen.
- Zacks
The Zacks Analyst Blog Highlights: Lear, SEI Investments, Alexion Pharmaceuticals and Apartment Investment and Management
The Zacks Analyst Blog Highlights: Lear, SEI Investments, Alexion Pharmaceuticals and Apartment Investment and Management
